III.L 0MSFT 0.31GO.U.TO 0.3CIU.PR.A.TO 0DAL -0.02CDZ.TO 0.42NET -0.42KLAC 1.81
Stryker Corp. (SYK)

NYSE:SYK

Stryker Corp. (SYK)

326.54
-0.00 (0.00%)
as of Jul 2, 2026, 9:00:20 pm Market Open.
258 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJul 5, 2026, 12:00 am

This summary was created by AI, based on 7 opinions in the last 12 months.

Stryker Corp (SYK) is facing a challenging environment in the medtech sector, characterized by weakness due to a post-Covid normalization and ongoing issues, including a cybersecurity attack that affected production. Despite these hurdles, experts largely recognize Stryker's strong market position, particularly in orthopedics, which continues to be a profitable segment for U.S. hospitals. The company has a robust relationship with medical professionals and is expected to grow its revenue at high single-digit rates. Analysts predict significant earnings growth, with a projected EPS of $15 by 2027, supported by an attractive valuation. As the population ages, the demand for artificial joints and robotic-assisted surgeries is expected to rise, positioning Stryker favorably in the long term.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
Pfeizer, PFE
TOP PICK

Stryker Corp.(SYK)

May 21, 2019
Medical devices company. Great company. Will continue to grow with the aging population. 73% of the business in the U.S., 23% in Europe and the rest emerging markets. Can grow their business internationally. Very little debt. Great story, great growth and operating margins. (Analysts’ price target is $201.12)
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$185.45

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
PAST TOP PICK

Stryker Corp.(SYK)

May 03, 2019
(A Top Pick Mar 21/18, Up 17%) Fantastic company in diverse medical devices. Leader in hip and knee replacements. Latest quarter was fantastic.
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$190.71

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Apr 22, 2019
Great company, trading cheap in the low-20's. It will do well as its competitors stumble.
Photo of Gordon ReidGordon ReidUnlock Rating
$182.16

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Apr 09, 2019
A great company that makes medical devices and does hip replacements. A surgeon that uses their equipment won't suddenly switch to another brand; the doctor will stay with Stryker. A problem is that sometimes the FDA approves medical devices too quickly--though that isn't a problem with Stryker. This is a good long-term hold.
Photo of Paul Harris, CFAPaul Harris, CFA
No
Unlock Rating
$195.97

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Stryker Corp.(SYK)

Mar 21, 2019
The valuation is about a 10-15% premium to the market. It has predictable growth and has done quite well. They have distinguished themselves in the way they can execute. He prefers this one to others in the space. He would be interested at a lower price.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$198.00

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Stryker Corp.(SYK)

Feb 15, 2019
Earnings in last quarter had 6-7% organic growth, 2-3 times better than the competition. Not cheap at 23x earnings. Has differentiated itself from the others in its industry. As long as dividends are growing at a hefty rate, no reason to sell.
Photo of David DriscollDavid DriscollUnlock Rating
$187.40

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Feb 13, 2019
A great medical tech company making equipment for knee replacements and spines. SYK spends a lot of time training doctors to use their equipment, which is not interchangeable with other manufacturers, so those doctors will continue to use SKY equipment. Demographics as society ages help SYK. Well-run, and it hit new highs today. This is a great story. Will do well long-term.
Photo of Paul Harris, CFAPaul Harris, CFAUnlock Rating
$185.63

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Feb 06, 2019
They do knee and hip replacements. SYK are active in tuck-in acquisitions which is quite accretive. They trade at a decent valuation. A consistent stock performer.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$180.70

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Feb 04, 2019
Has grown its dividend 12% compounded over 5 years. A great international growth story in medical devices. They continue to invest in new technology. They're gaining market share. They're using robots to speed up operations with fewer problems. (Analysts’ price target is $190.40)
Photo of John O'Connell, CFAJohn O'Connell, CFA
Owned
Unlock Rating
$176.29

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Nov 20, 2018
His focus on healthcare equipment. Demographically positive. They make artificial knees and hips, and have introduced robots. Has held in well in market uncertainty. Will be developing more and more technologies. Yield is 1.1%. (Analysts’ price target is $185.27)
Photo of Zachary Curry Zachary Curry
Owned
Unlock Rating
$165.95

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Stryker Corp.(SYK)

Oct 12, 2018

(A Top Pick August 21/17, Up 20%) Hips and knees. Robotic surgery and 3D printers. His fear is that Stryker will buy Globus, and the subsidiary will overtake the parent.

Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$171.04

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Stryker Corp.(SYK)

Sep 12, 2018

This is a great company, he says, with a well-established track record. The price is getting to the point, where you are paying a premium at this level. He would diversify into other holdings as well, ideally through an ETF such as IHI-N

Photo of Cameron HurstCameron Hurst
No
Unlock Rating
$173.29

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Stryker Corp.(SYK)

Aug 07, 2018

They make bespoke equipment. This can never be Amazon’d because the representative from Stryker works so closely with the doctor when they implant a new device into a patient. They are well-run, their robotics are leading edge. He likes the sector and this individual company but he would manage the idiosyncratic risk in this space by buying the IHI (US medical devices) ETF.

Photo of Cameron HurstCameron Hurst
No
Unlock Rating
$165.18

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Aug 07, 2018

Compared to the competition, Stryker has 8% organic growth due to hips and knees business. Robotics for knees and 3D printers for hips are giving them an edge. Dividend’s been rising 14-15% per year. The premier medical device company. Yield is 1.1%. (Analysts’ price target is $182.10)

Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$165.18

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Jul 05, 2018

They are growing on robotics. On knee and hip are going to be the dominant player. It is the new wave.

Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$171.33

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
Showing 106 to 120 of 171 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NFLX 0$77.65
GOOG -0.5$355.68
CAT 1.47$965
NFLX 0$77.65
AAPL -0.2$308.43

Today's Top Picks

III.L 0$2999
MSFT 0.31$390.8
GO.U.TO 0.3$9.55
CIU.PR.A… 0$
DAL -0.02$92.73

Popular Articles

Latest Sell Signals

CAT 1.47$965
ASML 5.87$1775.1899
TRI.TO -1.74$124.88
EIF.TO 2.09$132.94
MU 0.84$976.4

Most Recent Experts

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

Josh Brown, CEO, Ritholtz Wealth Management

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Michael Hakes - CFA, MBA

Michael Hakes - CFA, MBA

Murray Wealth Group

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like